Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 18/20 | 0.64 |
| ▸ | MMP2 | P08253 | 16/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.64 |
| ▸ | MMP9 | P14780 | 10/20 | 0.64 |
| ▸ | MMP3 | P08254 | 3/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177025 | 1.00 | ADAM10 (0.64) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL2174364 | 0.86 | ADAM10 (0.63) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL2176086 | 0.85 | ADAM10 (0.61) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL2177249 | 0.85 | ADAM10 (0.61) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL2173828 | 0.84 | ADAM10 (0.60) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL2174820 | 0.84 | ADAM10 (0.63) | ADAM10MMP2ERBB2MMP9MMP3 | |
| Trifluoroacetic Acid SCHEMBL2177021 | 0.83 | ADAM10 (0.67) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL2175012 | 0.83 | ADAM10 (0.58) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL2174572 | 0.83 | ADAM10 (0.58) | ADAM10MMP2ERBB2MMP9MMP3 | |
| Trifluoroacetic Acid SCHEMBL2174362 | 0.79 | ADAM10 (0.67) | ADAM10MMP2ERBB2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | ADAM10 25/4885MMP2 5/4885ERBB2 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.